corest inhibitor tng260

Generic: CoREST Inhibitor TNG260

corest inhibitor tng260: sourced relationships with 1 company · 1 clinical trial tracked.

What we can confirm

1 tracked trial

Tango Therapeutics, Inc. (TNGX)

What it means

Source-backed records connect corest inhibitor tng260 to TNGX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.

BioSniper AIPage evidence connected

Prepared research question

How could corest inhibitor tng260 → TNGX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Related indications

Non Small Cell Lung Cancer Lung Adenocarcinoma Lung Cancer

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)

Company	Dated record stage	Indication
Tango Therapeutics, Inc. (TNGX) developer · Reported 2026-03-05 · Current development: unknownSource Non Small Cell Lung Cancer	Phase 1/Phase 2	Non Small Cell Lung Cancer

Clinical Trial Registry Records (1)

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors

NCT05887492Registry updated 2026-07-06·Phase 1/Phase 2·TNGX

Active, not recruiting

Primary endpoint: Determine the MTD and RP2D(s) (Phase 1 only)

Interventionalopen126 targetStarted 2023-06Completion 2026-0913 sites · United StatesTango Therapeutics, Inc.

Frequently asked questions

Which companies have sourced relationships with corest inhibitor tng260?

corest inhibitor tng260 has dated SEC/FDA relationship records for Tango Therapeutics, Inc..

How many clinical trials involve corest inhibitor tng260?

BioSniper tracks 1 clinical trial involving corest inhibitor tng260.